Clinical Trials Sponsored by Zosano Pharma Corporation

Total 460 results

Alfonso Fasano
Boston Scientific Corporation

Not yet recruiting

Directional Bilateral Thalamic Patterned Stimulation (Chronos)

Essential Tremor

Canada
Bayer
Orion Corporation, Orion Pharma

Completed

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (ARASENS)

Metastatic Hormone-sensitive Prostate Cancer

Belgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Malignant Brain Tumor

United States
Ophthotech Corporation

Completed

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Completed

A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Ophthotech Corporation

Completed

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Wet Age-related Macular Degeneration

United States, Hungary, Latvia
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Israel, United States, Germany, Denmark, France, Turkey, Hungary, Colombia, Australia, Argentina, Spain
Ophthotech Corporation

Completed

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

Age-related Macular Degeneration

United States
Ophthotech Corporation

Completed

ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Withdrawn

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Ophthotech Corporation

Completed

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan
NewLink Genetics Corporation

Terminated

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
NewLink Genetics Corporation

Withdrawn

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Cancer | Ovarian Cancer | Solid Tumor

United States
NewLink Genetics Corporation

Terminated

Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor Malignancy

United States
NewLink Genetics Corporation

Completed

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Glioma | Glioblastoma Multiforme | Gliosarcoma | Ependymoma | Medulloblastoma | Diffuse Intrinsic Pontine Glioma | Malignant Brain Tumor | Primary CNS Tumor

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Solid Tumors

United States
NewLink Genetics Corporation

Completed

Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
NewLink Genetics Corporation

Completed

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Completed

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Poland
NewLink Genetics Corporation

Terminated

Vaccine Treatment for Advanced Breast Cancer

Breast Cancer

United States
Bayer
Orion Corporation, Orion Pharma

Completed

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

Prostatic Neoplasms

Germany
AstraZeneca
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)

Bronchial Asthma

Japan
Orion Corporation, Orion Pharma
Bayer

Completed

Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects (ARIADME)

Healthy

United Kingdom
Novartis
Mitsubishi Tanabe Pharma Corporation

Completed

An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis

Japan
Novartis
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

Multiple Sclerosis

Japan
AstraZeneca
Mitsubishi Tanabe Pharma Corporation

Completed

Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

Non-erosive Reflux Disease

Japan
Abbott
Orion Corporation, Orion Pharma

Completed

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

Heart Failure, Congestive

United States, Israel, Australia, Canada
Bayer
Orion Corporation, Orion Pharma

Active, not recruiting

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE)

Prostatic Neoplasms

China, Russian Federation, Taiwan, Latvia, India, Australia, Brazil, Canada, Chile, Lithuania, New Zealand, Peru, South Africa, Spain, Ukraine
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Completed

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Age-related Macular Degeneration
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
NewLink Genetics Corporation

Completed

Vaccine Treatment for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Terminated

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors (D-1MT)

Melanoma | Breast Cancer | Pancreatic Cancer | Lung Cancer | Solid Tumors

United States
NewLink Genetics Corporation

Completed

Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers

Healthy

Canada
NewLink Genetics Corporation

Terminated

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

Pancreatic Cancer | Pancreatic Carcinoma Non-resectable

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

Pancreatic Cancer | Locally Advanced Malignant Neoplasm | Pancreatic Carcinoma Non-resectable

United States
NewLink Genetics Corporation

Terminated

Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
NewLink Genetics Corporation

Completed

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers (NLG2111)

Healthy

United States
NewLink Genetics Corporation

Completed

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Cancer | Solid Tumor

United States
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
AstraZeneca
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)

Bronchial Asthma

Japan
AstraZeneca
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)

Chronic Obstructive Pulmonary Disease (COPD)

Japan
AstraZeneca
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

Non-erosive Reflux Disease

Japan
Ophthotech Corporation

Terminated

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Age-related Macular Degeneration

United States
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Italy, Canada, Switzerland, United States, United Kingdom, Austria, Belgium, Brazil, Czechia, Estonia, Latvia, Poland, Slovakia

Clinical Trials Sponsored by Zosano Pharma Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations